Evidence map›Paper›PMID 38951457›Full record

ArticleJournal of neuro-oncology2024

Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era.

Kyril L Cole, Emma R Earl, Matthew C Findlay, Brandon A Sherrod, Samuel A Tenhoeve, Jessica Kunzman, Donald M Cannon, Wallace Akerley, Lindsay Burt, Seth B Seifert and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kyril L ColeSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Emma R EarlSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Matthew C FindlaySchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Brandon A SherrodDepartment of Neurosurgery Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT, 84132, USA.
Samuel A TenhoeveSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Jessica KunzmanSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Donald M CannonDepartment of Radiation Oncology, University of Utah, Salt Lake City, UT, USA.
Wallace AkerleyDepartment of Medical Oncology, University of Utah, Salt Lake City, UT, USA.
Lindsay BurtDepartment of Radiation Oncology, University of Utah, Salt Lake City, UT, USA.
Seth B SeifertSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
Matthew GoldmanDepartment of Neurosurgery, University of Florida, Gainesville, FL, USA.
Randy L JensenDepartment of Neurosurgery Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT, 84132, USA. neuropub@hsc.utah.edu.ORCID https://orcid.org/0000-0002-2824-4221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTargeted treatment options for non-small cell lung cancer (NSCLC) brain metastases (BMs) may be combined with stereotactic radiosurgery (SRS) to optimize survival. We assessed patient outcomes after SRS for NSCLC BMs, identifying survival trajectories associated with targetable mutations.

methodsIn this retrospective time-dependent analysis, we analyzed median overall survival of patients who received ≥ 1 SRS courses for BM from NSCLC from 2001 to 2021. We compared survival of patients with and without targetable mutations based on clinical variables and treatment.

resultsAmong the 213 patients included, 87 (40.8%) had targetable mutations-primarily EGFR (22.5%)-and 126 (59.2%) did not. Patients with targetable mutations were more often female (63.2%, p <.001) and nonsmokers (58.6%, p <.001); had higher initial lung-molGPA (2.0 vs. 1.5, p <.001) and lower cumulative tumor volume (3.7 vs. 10.6 cm

conclusionThe presence of targetable mutations enhances survival in patients receiving SRS for NSCLC BM, particularly when used with systemic therapies. Survival for patients without targetable mutations was longest with SRS and surgical resection. These results inform best practices for managing patients with NSCLC BM based on driver mutation status.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationRadiosurgeryAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateBrain metastasesNon-small cell lung cancerPrimary lung cancerPrognosisStereotactic radiosurgeryTargeted therapy

Identifiers

PMID38951457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.